FeverTree posts strong first-half profit as US growth accelerates

Fevertree Drinks reported first-half adjusted brand revenue growth of 8% at constant currency to £183.6 million for the six months ended 30 June, while adjusted EBITDA increased 9% to £20.1 million. Growth was supported by accelerating US sales under its Molson Coors partnership and a return to growth in the UK business, indicating improved momentum across its two key markets.

Analysis

FEVR’s investment case is shifting from a premium mixer brand with US distribution constraints to an asset-light route-to-market beneficiary of TAP’s scale. The key underwriting question is whether the partnership converts distribution gains into repeat velocity without requiring a proportional increase in trade spend; if it does, incremental US revenue should carry materially higher contribution margins than direct-market buildout. TAP gains a premium, non-beer adjacency that can improve wholesaler relevance and on-premise account penetration, but the financial impact is unlikely to be material to its consolidated earnings over the next 12 months.

Near-term, FEVR’s rerating depends less on reported growth than on evidence that US growth is broad-based across measured retail, club and on-premise rather than partner inventory loading. Over the next 1-3 months, monitor Nielsen/IRI velocity, US gross-margin progression and management commentary on promotional intensity; sustained double-digit US sell-through would support upgrades to FY estimates and multiple expansion. A reversal in UK consumer demand, renewed glass/freight inflation, or evidence that TAP’s distributor economics require elevated allowances would quickly challenge the operating-leverage thesis.

Contrarian view: the market may over-credit the partnership before seeing proof of consumer pull-through. TAP’s distributor network can accelerate placements, but premium tonic remains discretionary and faces private-label and large-spirit-company mixer competition when household budgets tighten. The more durable 6-18 month upside is not merely US revenue growth: successful premium mixer distribution could make FEVR a strategically scarce non-alcoholic/premium adult-beverage acquisition asset for TAP, STZ or DEO, though this should not be the core thesis absent evidence of sustained US profitability.

Key Decisions for Investors

• Initiate/maintain a tactical long FEVR over the next 1-3 months only if US scanner-data sell-through remains ahead of reported growth and FY EBITDA consensus begins to move higher; target a 15-20% upside from estimate revisions and rerating, with a 8-10% stop if US velocity or gross margin disappoints.
• Use long FEVR / short TAP as a relative-value expression for investors seeking exposure to US mixer execution: FEVR has direct earnings sensitivity to distribution productivity, while TAP’s absolute P&L benefit is diluted. Reassess after the next TAP results commentary on distributor incentives and depletion trends.
• Do not chase FEVR solely on first-half earnings; set an alert for a reduction in UK growth or guidance that implies higher US selling expense. Either would indicate that revenue growth is being purchased rather than converted into scalable EBITDA.
• For TAP holders, treat the partnership as a modest strategic positive rather than an earnings catalyst; maintain position sizing based on beer volumes, pricing and input-cost outlook, not FEVR-related optionality.